• Explore /
  • Poster
  • / Rate of conversion from unresectable to resectable metastatic colorectal cancer (mCRC) in real-world patients (RWP) treated with FOLFIXIRI ± bevacizumab: A population-based retrospective cohort study.

Rate of conversion from unresectable to resectable metastatic colorectal cancer (mCRC) in real-world patients (RWP) treated with FOLFIXIRI ± bevacizumab: A population-based retrospective cohort study.

Abstract Poster

Authors

null

Tayyaba Bhatti

College of Medicine, University of Saskatchewan, Saskatoon, SK, Canada

Tayyaba Bhatti , Michael Moser , Jon Tan , Adnan Zaidi , Duc Le , Haji I. Chalchal , John Shaw , Selliah Kanthan , mussawar iqbal , Yigang Luo , Kamal Haider , Tehmina Asif , Dueck Dorie-Anna , Dilip Gill , Nathan Ginther , Shahid Ahmed

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session C: Anal and Colorectal Cancer

Track

Colorectal Cancer,Anal Cancer

Sub Track

Patient-Reported Outcomes and Real-World Evidence

Citation

J Clin Oncol 38, 2020 (suppl 4; abstr 21)

Abstract #

21

Poster Bd #

A15

Abstract Disclosures

Similar Posters

First Author: Shahid Ahmed

First Author: Yanhong Deng

First Author: Johanna C. Bendell

First Author: Thomas Gruenberger